Cargando…

Pharmacological targeting of PI3K isoforms as a therapeutic strategy in chronic lymphocytic leukaemia

PI3Kδ inhibitors such as idelalisib are providing improved therapeutic options for the treatment of chronic lymphocytic leukaemia (CLL). However under certain conditions, inhibition of a single PI3K isoform can be compensated by the other PI3K isoforms, therefore PI3K inhibitors which target multipl...

Descripción completa

Detalles Bibliográficos
Autores principales:	Blunt, Matthew D., Steele, Andrew J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2015
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4588368/ https://www.ncbi.nlm.nih.gov/pubmed/26500849 http://dx.doi.org/10.1016/j.lrr.2015.09.001

Ejemplares similares

CK2 and PI(3)K are direct molecular targets of quercetin in chronic lymphocytic leukaemia
por: Russo, Maria, et al.
Publicado: (2017)

Functional redundancy of PI3K isoforms in conventional T cells provides a selective Treg-targeting strategy through inhibition of PI3K-delta isoform
por: Ahmad, Shamim, et al.
Publicado: (2014)

Therapeutic approaches and drug-resistance in chronic lymphocytic leukaemia
por: Fatima, Narjis, et al.
Publicado: (2020)

PYK2 is overexpressed in chronic lymphocytic leukaemia: A potential new therapeutic target
por: Sbrana, Francesca Vittoria, et al.
Publicado: (2023)

The AKT1 isoform plays a dominant role in the survival and chemoresistance of chronic lymphocytic leukaemia cells
por: Hofbauer, Sebastian W., et al.
Publicado: (2015)

Drugging PI3K in cancer: refining targets and therapeutic strategies
por: Yap, Timothy A, et al.
Publicado: (2015)

EZH2 upregulates the PI3K/AKT pathway through IGF1R and MYC in clinically aggressive chronic lymphocytic leukaemia
por: Kosalai, Subazini Thankaswamy, et al.
Publicado: (2019)

Immunotherapy in Chronic Lymphocytic Leukaemia (CLL)
por: Freeman, Ciara L., et al.
Publicado: (2016)

Therapeutic Potency of PI3K Pharmacological Inhibitors of Gastrointestinal Cancer
por: Hashemzadeh, Kamelia, et al.
Publicado: (2019)

Aberrant PI3Kδ splice isoform as a potential biomarker and novel therapeutic target for endocrine cancers
por: Ha, Siyoung, et al.
Publicado: (2023)

The role of PI3Kα isoform in cardioprotection
por: Rossello, Xavier, et al.
Publicado: (2017)

Can ELABELA be a novel target in the treatment of chronic lymphocytic leukaemia?
por: Acik, Didar Yanardag, et al.
Publicado: (2019)

Strategies For Targeting Chronic Myeloid Leukaemia Stem Cells
por: Carrà, Giovanna, et al.
Publicado: (2019)

Targeted PI3K/AKT-hyperactivation induces cell death in chronic lymphocytic leukemia
por: Ecker, Veronika, et al.
Publicado: (2021)

The Mysterious Actor—γδ T Lymphocytes in Chronic Lymphocytic Leukaemia (CLL)
por: Zarobkiewicz, Michał K., et al.
Publicado: (2022)

A case of leukaemia cutis in a dog with T‐cell chronic lymphocytic leukaemia
por: Bae, Hyeona, et al.
Publicado: (2022)

Ribosomal RNA Synthesis in Chronic Lymphocytic Leukaemia
por: Billington, R. W., et al.
Publicado: (1974)

NICE recommends acalabrutinib for chronic lymphocytic leukaemia
Publicado: (2021)

Structural Determinants of Isoform Selectivity in PI3K Inhibitors
por: Miller, Michelle S., et al.
Publicado: (2019)

Heterogeneity of Phosphatidylinositol-3-Kinase (PI3K)/AKT/Mammalian Target of Rapamycin Activation in Cancer: Is PI3K Isoform Specificity Important?
por: Cintas, Célia, et al.
Publicado: (2018)

Derivatisation of parthenolide to address chemoresistant chronic lymphocytic leukaemia
por: Li, Xingjian, et al.
Publicado: (2019)

An updated perspective on immunoglobulin replacement in chronic lymphocytic leukaemia in the era of targeted therapies
por: Khan, Sujoy, et al.
Publicado: (2023)

Therapeutic Targeting of the Leukaemia Microenvironment
por: Kuek, Vincent, et al.
Publicado: (2021)

The Spliceosome: A New Therapeutic Target in Chronic Myeloid Leukaemia
por: Lebecque, Benjamin, et al.
Publicado: (2022)

The Uptake and Utilization of Chlorambucil by Lymphocytes from Patients with Chronic Lymphocytic Leukaemia
por: Hill, Bridget T., et al.
Publicado: (1972)

Colonic Involvement in a Patient with Chronic Lymphocytic Leukaemia
por: Arkkila, P. E. T., et al.
Publicado: (2008)

Chronic lymphocytic leukaemia during pregnancy: management and thoughts
por: Winckler, Patricia, et al.
Publicado: (2015)

The clinical implications of gene mutations in chronic lymphocytic leukaemia
por: Rossi, Davide, et al.
Publicado: (2016)

Acalabrutinib for mantle cell lymphoma, chronic lymphocytic leukaemia
Publicado: (2020)

COVID-19 in a patient with chronic lymphocytic leukaemia
por: Jin, Xiang-Hong, et al.
Publicado: (2020)

Chronic Lymphocytic Leukaemia in 2020: the Future Has Arrived
por: Milne, Kate, et al.
Publicado: (2020)

Whipple’s Disease as the First Manifestation of Chronic Lymphocytic Leukaemia
por: Guiomar, Verónica, et al.
Publicado: (2019)

Will New Drugs Replace Transplants for Chronic Lymphocytic Leukaemia?
por: Yang, Shenmiao, et al.
Publicado: (2021)

An Unusual Case of Chronic Lymphocytic Leukaemia Involving the Cervix
por: Hamer, Jack, et al.
Publicado: (2022)

Perspectives on the Application of Cytogenomic Approaches in Chronic Lymphocytic Leukaemia
por: Wan Mohamad Zamri, Wan Norizzati, et al.
Publicado: (2023)

Expert consensus on the management of chronic lymphocytic leukaemia in Asia
por: Tse, Eric, et al.
Publicado: (2023)

Divergent Roles of PI3K Isoforms in PTEN-Deficient Glioblastomas
por: Xie, Shaozhen, et al.
Publicado: (2020)

Management of toxicity to isoform α-specific PI3K inhibitors
por: Nunnery, S E, et al.
Publicado: (2019)

Genomic disruption of the histone methyltransferase SETD2 in chronic lymphocytic leukaemia
por: Parker, H, et al.
Publicado: (2016)

Targeting Mitochondrial Bioenergetics as a Therapeutic Strategy for Chronic Lymphocytic Leukemia
por: Roy Chowdhury, Subir, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_puk2rvkge9k7qcgqp3f5anqb2a